¶ÈÀÓ¾Ò²ð

2011ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Ashitani M, Ueno C, Doi T, Kinoshita T, Tomoda K ; Clinical features of functional hearing loss with inattention problem in Japanese children.International journal of pediatric otorhinolaryngology 75(11)1431-5
  2. Canuet L, Ishii R, Pascual-Marqui RD, Iwase M, Kurimoto R, Aoki Y, Ikeda S, Takahashi H, Nakahachi T, TakedaM ; Resting-state EEG source localization and functional connectivity in schizophrenia-like psychosis of epilepsy.PLoSONE 6(11)Article No.e27863
  3. Hilty L, Langer N, Pascual-Marqui R, Boutellier U, LutzK ; Fatigue-induced increase in intracortical communication between mid/anterior insular and motor cortex during cycling¡¡exercise.The European journal of neuroscience¡¡34(12)2035-42
  4. Kikuchi M, Hashimoto T, Nagasawa T, Hirosawa T, MinabeY, Yoshimura M, Strik W, Dierks T, Koenig T ; Frontal areas¡¡contribute to reduced global coordination of resting-state¡¡gamma activities in drug-naïve patients with schizophrenia. Schizophrenia Research ; 130(1-3):187-194
  5. Nishida K, Yoshimura M, Isotani T, Yoshida T, Kitaura Y, SaitoA, Mii H, Kato M, Takekita Y, Suwa A, Morita S, Kinoshita T ; Differences in quantitative EEG between frontotemporal dementia and Alzheimer's disease as revealed by LORETA. Clinical neurophysiology 122(9)718-1725
  6. Pascual-Marqui RD, Lehmann D, Koukkou M, Kochi K,¡¡Anderer P, Saletu B, Tanaka H, Hirata K, John ER, PrichepL, Biscay-Lirio R, Kinoshita T ; Assessing interactions in thebrain with exact low-resolution electromagnetic tomography.Philosophical transactions.Series A, Mathematical, physical,and engineering sciences 369(1952):3768-3784
  7. Takekita Y, Kato M, Sakai S, Suwa A, Nishida K, Tajika A,Yoshimura M, Kinoshita T ; Olfactory reference syndrometreated by blonanserin augmentation. Psychiatry and clinical neurosc iences 65(2)203-204
  8. Tanino Y, Yoneda H, Takasaki K, Suzuki T, Watanabe M, Kono K, Yokono A, Matsuoka T, Hatashita Y, Kinoshita T ; Reach distance and movement strategy patterns during the functional reach test of psychiatric patients.Journal of Physical Therapy Science23(4)655-659
  9. ÊÒ¾åůÌé, ºû²¬²ÂÈþ, ¿¥ÅÄ͵¹Ô, ÌÚ²¼Íøɧ ; ¿ÈÂμÀ´µ¤«¤é¤»¤óÌѤ¬¼æµ¯¤µ¤ì¤¿Àº¿Àɾɾõ¤òȼ¤¦ÁжËI ·¿¾ã³²¤Î1Îã.Bipolar disorder/Japan 9:29-34
  10. ¼ÅÄÃι¯, À¾ÅÄ·½°ìϺ, ÖÖË̲µ±, ßÀ¡¡Íýº», Ë̱ºÍ´°ì, »°°æ¡¡¹À, Pascua-MarquiRobert D., µÈ¼¶©»Ë, ÀÄú˱§°Ê, ±§ÅԵܷ¼ÂÀ, ÌÚ²¼Íøɧ ; ½¤Àµ·¿Åŵ¤áÛÚ»ÎÅË¡(m-ECT)¤¬Ãø¸ú¤·¤¿¤¦¤ÄɤξÉÎã¤Ë¤ª¤±¤ëÄêÎÌǾÇȲòÀÏ. ÆüËÜÌôʪǾÇȳزñ»¨»ï12(1)47-51
  11. ¿¥ÅÄ͵¹Ô, ÊÒ¾åůÌé, »³ÅÄÈÞº»»Ò, »³ÅÄ·½Â¤, ÌðÌî͵»Ò, ²¬Â¼¹¨Èþ, ÃæÊ¿¶Ç»Ò, µÈÌî¿¿µª, ÎëÌÚÈþº´, ÌÚ²¼Íøɧ ; ¥Û¥ë¥â¥óÎÅË¡¤¬FTM ¤ÎÀº¿ÀÌ̤ËÍ¿¤¨¤ë±Æ¶Á. ÆüËÜÀ­²Ê³Ø²ñ»¨»ï29(1)51-57
  12. ÖÖË̲µ±¡¤ºä°æ»ÖÈÁ¡¤Â¼ÅÄÃι¯¡¤¿¥ÅÄ͵¹Ô¡¤ÅĶᰡÍö¡¤µÈ¼¶©»Ë¡¤²ÃÆ£Àµ¼ù¡¤ÌÚ²¼Íøɧ ; Âç³Øɱ¡³°Íè¤Ë¤ª¤±¤ërisperidone»ý¸úÀ­Ãí¼ÍÀ½ºÞ¤Î»ÈÍѷи³.¡¡ËýÀ­´üÅý¹ç¼ºÄ´¾É¤ª¤è¤Ó¼ºÄ´´¶¾ð¾ã³²´µ¼Ô57Îã¤ËÂФ¹¤ë6¥õ·î´Ö¤ÎÎ×¾²Åª¸¡Æ¤¡¥Áí¹çɱ¡Àº¿À°å³Ø23(3)287-294
  13. °¤Éô¡¡¾°¡¤ÖÖË̲µ±¡¤²ÃÆ£Àµ¼ù¡¤ÌÚ²¼Íøɧ ; ¾ÉÎ㤫¤é³Ø¤Ö- ¿·¤·¤¤Ìô¤ò»È¤¤¤³¤Ê¤¹¤Ë¤Ï ¥ß¥ë¥¿¥¶¥Ô¥ó¤ÎÍ­¸úÀ­- ´û¸¤Î¹³¤¦¤ÄÌô¤Ë¤è¤ë¼£ÎŤ¬º¤Æñ¤Ç¤¢¤Ã¤¿Â礦¤ÄÉÂÀ­¾ã³²¤Î¾ÉÎã¤òÄ̤·¤Æ-. Àº¿À²Ê18(2)123-127
  14. ÌÚ²¼Íøɧ¡¤È¬ÌÚÆ»Éס¤°Â°æ²Å°ì¡¤¸¶¡¡Æػҡ¤ÃÝÆâ´²»Ò¡¤Âç½»¹§É§¡¤Åì ¡¡¹À¼¨, »³ºêÍ­Èþ»Ò ; ·ò¹¯À®¿ÍÃËÀ­¤Ë¤ª¤±¤ë¥¢¥ê¥Ô¥×¥é¥¾¡¼¥ë3mg ÉáÄ̾û1 ¾û¤È¥¢¥ê¥Ô¥×¥é¥¾¡¼¥ë3mg ¸ý¹ÐÆâÊø²õ¾û1 ¾û¤ÎÀ¸Êª³ØŪƱÅùÀ­»î¸³. ÌôÍý¤È¼£ÎÅ39(11)949-960
  15. ºû²¬²ÂÈþ¡¤ÅĶᰡÍö¡¤ÊÒ¾åůÌ顤ÖÖË̲µ±¡¤±§ÌîÅĹ乨¡¤ºä°æ»ÖÈÁ¡¤Æ£»³²íÀ²¡¤²ÃÆ£Àµ¼ù¡¤±§ÅԵܷ¼ÂÀ¡¤
    ÌÚ²¼Íøɧ ; Topiramate ¤ÈPhenytoin ¤¬Í­¸ú¤Ç¤¢¤Ã¤¿¸¸³ÐÌÑÁۤȹâÍȵ¤Ê¬¤ò¤È¤â¤Ê¤¦Á°Æ¬ÍդƤ󤫤ó¤Î1 Îã. Âçºå¤Æ¤ó¤«¤ó¸¦µæ²ñ»¨»ï22(1)29-33
  16. ²¬Â¼¹¨Èþ¡¤µÈÌî¿¿µª¡¤ÌÚ²¼Íøɧ¡¤¶á¾¾Åµ»Ò ; ¡ÖÀ¸¤­¤ë¤Î¤ò¤â¤¦¾¯¤·³Ú¤Ë¤·¤¿¤¤¡×¤ÈÍèÃ̤·¤¿ÀÄǯ¤È¤ÎÌÌÃ̲áÄø. ÀÄǯ´üÀº¿ÀÎÅË¡8(1)65-71
  17. ¹âÌî¡¡È»¡¤¿ù»³Í´Éס¤ÖÖË̲µ±¡¤Â¼¾åµ®±É¡¤³Á±Ê²ÂÎɻҡ¤»³ËÜÆػҡ¤ÌÚ²¼Íøɧ ; Àº¿À¾ã¤¬¤¤¼Ô¤ËÂФ¹¤ëÃϰ豿ư¥×¥í¥°¥é¥à¤ÎÍ­ÍÑÀ­¡ÝÅý¹ç¼ºÄ´¾É¤ÈÀº¿À¾ã¤¬¤¤¼Ô¥µ¥Ã¥«¡¼¥¢¥«¥Ç¥ß¥¢¤Î½Ð²ñ¤¤¡Ý. ºî¶ÈÎÅË¡30(6)745-750
  18. µÈÌî¿¿µª¡¤ÅĶᡡʸ¡¤¾åÌîÀéÊ桤ÌÚ²¼Íøɧ ; ¿À·Ð¾É·÷´µ¼Ô¤Ë¤ª¤±¤ëû´ü¿´ÍýÎÅË¡¤Ë¤è¤ë»Ù±ç Âç³Øɱ¡Àº¿À¿À·Ð²Ê³°Íè¤Ç¤Î¼ÂÁ©¤«¤é. ¥á¥ó¥¿¥ë¥Ø¥ë¥¹²¬Ëܵ­Ç°ºâÃĸ¦µæ½õÀ®Êó¹ð½¸22:105-110
  19. ÎëÌÚÊþ»Ò¡¤µÈÌî¿¿µª¡¤ÅĶᡡʸ¡¤ËÙÆâËãÈþ¡¤±üÀî¡¡³Ø¡¤ÌÚ²¼Íøɧ ; Àº¿ÀÎÅË¡¤Ë¤ª¤±¤ë´µ¼Ô¤Î´¶¾ð¤ÎÊѲ½¡¡²»À¼ÊªÍýÎ̤ȸÀ¸ìÆâÍƤδØÏ¢¤Ë¤Ä¤¤¤Æ¤Î¸¡Æ¤¡¥¥á¥ó¥¿¥ë¥Ø¥ë¥¹²¬Ëܵ­Ç°ºâÃĸ¦µæ½õÀ®Êó¹ð½¸21:45-48
  20. Ê÷´ßͳµª»Ò¡¤°ëë½ÓÌÀ¡¤µÈ¼¶©»Ë¡¤»³ÅÄ·½Â¤¡¤À¾ÅÄ·½°ìϺ¡¤¿¹ÅļÓÀ顤óîÆ£¹¬»Ò¡¤Æþß·¡¡ÁÌÚ²¼Íøɧ¡¤
    ÌÚ¸¶¡¡Íµ ; ³ÔÎÓ¿·µ¤¸ù¤¬¶õ´ÖŪǾÅŰ̳çÆ°¤Ë¤â¤¿¤é¤¹±Æ¶Á( Âè3¡¦4Êó). ºÅ̲¤È²Ê³Ø25(1)48-54
  21. ÉÛë·òÂÀϺ, ¿ù»³Å¯Ìé, ¾®ÄÕ¾ÍÂÀ, ¿¢ÌÚËãÍý, ¿ûß·¡¡½ß,ÃÓÅűɧ, À¾ÅÄ·½°ìϺ, ±§ÅԵܷ¼ÂÀ ; Àµ¾ï´ã°µÎÐÆâ
    ¾ã¤È¤·¤ÆĹ´ü·Ð²á¤·¤¿¸å¤ËAlzheimer ɤòȯ¾É¤·¤¿1 ¾ÉÎã. ¤¢¤¿¤é¤·¤¤´ã²Ê28(8)122-126

¥Ú¡¼¥¸TOP¤ØÌá¤ë

ÁíÀ⡦²òÀâ

  1. ÈÄÅ침¼ù¡¤¿ùËÜãºÈ¡¤»³ÅÄÈÞº»»Ò¡¤»°°æ¡¡¹À¡¤¿¥ÅÄ͵¹Ô¡¤Ê¿Àɧ¡¤Â¼Èø²Â§¡¤ÃæëÔèÃË¡¤ÌÚ²¼Íøɧ ; ²áÎÌÉþÌô´µ¼Ô¤Î¿´ÍýŪŽ¥¼Ò²ñŪÇطʤÈͽËɺö. ÃæÆǸ¦µæ24(1)9-15
  2. ÊÒ¾åůÌ顤ÌÚ²¼Íøɧ ; ÁжËÀ­¾ã³²¤Î¿·¤·¤¤¼£ÎÅÌô:³¤³°Ã諤òÃæ¿´¤È¤·¤Æ 2)Äê·¿¹³Àº¿ÀÉÂÌô¤ÎÁжËÀ­¾ã³²¤Ø¤ÎÎ×¾²ÅªÅ¬±þ. Î×¾²Àº¿À°å³Ø40(7)949-958
  3. ÊÒ¾åůÌé ; ¤¦¤ÄÉÂÀ­º®¹ç¾õÂ֤ˤª¤±¤ëÉÔ°ÂŽ¥¾ÇÁç´¶Âкö¤Î½ÅÍ×À­. Î×¾²Àº¿ÀÌôÍý14(2)357-364
  4. ÊÒ¾åůÌé ; ÁжËÀ­º®¹ç¾õÂ֤ˤª¤±¤ëÉÔ°ÂŽ¥¾ÇÁç´¶Âкö¤Î½ÅÍ×À­. ºÇ¿·Àº¿À°å³Ø16(1)39-44
  5. ²ÃÆ£Àµ¼ù ; ÃíÌܤÎÏÀʸ¡¦¹Í»¡¡¡¹³¤¦¤ÄÌô¤È¼«»¦. ¤¦¤ÄÉ¡¥Selected Papers 1(1)9-11
  6. ²ÃÆ£Àµ¼ù¡¤ÌÚ²¼Íøɧ ; Lamotrigine ¤Ï¥à¡¼¥É¥¹¥¿¥Ó¥é¥¤¥¶¡¼¤«¡© ¡¥Î×¾²Àº¿ÀÌôÍý14(9)1479-1488
  7. ²ÃÆ£Àµ¼ù ; ºÇ¿·¤¦¤ÄÉ¥ȥԥ寥¹ ¹³¤¦¤ÄÌô¤Ë¤è¤ë¥ª¡¼¥À¡¼¥á¥¤¥É°åÎŤòÌܻؤ·¤Æ.D¡¦PLUS:vol.15:4-6
  8. ÌÚ²¼Íøɧ ; ¤¦¤ÄɤÎÊÑÁ«¤ÈÌôʪÎÅË¡. Éۻܰå»Õ²ñ»¨»ï72:33-35
  9. À¾ÅÄ·½°ìϺ¡¤²ÃÆ£Àµ¼ù¡¤ÖÖË̲µ±¡¤ÌÚ²¼Íøɧ ; ÁжËÀ­¾ã³²¤ÈÉ԰¾㳲¤Îcomorbidity. ºÇ¿·Àº¿À°å³Ø16(1)27-32
  10. ¿¥ÅÄ͵¹Ô¡¤ÊÒ¾åůÌ顤»³ÅÄÈÞº»»Ò¡¤»³ÅÄ·½Â¤¡¤ÌðÌî͵»Ò¡¤²¬Â¼¹¨Èþ¡¤ÃæÊ¿¶Ç»Ò, µÈÌî¿¿µª¡¤ÎëÌÚÈþº´¡¤ÌÚ²¼Íøɧ ; À­Æ±°ìÀ­¾ã³²(GID)¡¡ÃÏ°è¤Ë¤ª¤±¤ë°åÎÅÏ¢·È. Àº¿À°å³Ø53(8)783-787
  11. ¿¥ÅÄ͵¹Ô ; À­Æ±°ìÀ­¾ã³²¤ò¤á¤°¤ë½ôÌäÂê¡Ý GID ¥¯¥ê¥Ë¥Ã¥¯±¿±Ä¤Î²ÝÂê¡Ý . Àº¿À¿À·Ð³Ø»¨»ï ; SS175-180,
  12. ÖÖË̲µ±¡¤ÌÚ²¼Íøɧ ; ºÇ¿·ÌôʪÎÅË¡ ¥é¥á¥ë¥Æ¥ª¥óRamelteon( ¥í¥¼¥ì¥àRozerem). ºÇ¿·Àº¿À°å³Ø16(2)183-191
  13. ÖÖË̲µ± ; Åý¹ç¼ºÄ´¾É¤ËÂФ¹¤ëperospirone ¤Èaripiprazole¤Î̵ºî°Ù³äÉÕÈæ³Ó»î¸³.
    Î×¾²Àº¿ÀÌôÍý14(2)342-348
  14. ÅĶᰡÍö¡¤ÌÚ²¼Íøɧ ; ¥ê¥¹¥Ú¥ê¥É¥ó»þ¸úÀ­Ãí¼ÍºÞ. ºÇ¿·Àº¿À°å³Ø16(1)57-62
  15. »³ÅÄÈÞº»»Ò¡¤¿ùËÜãºÈ¡¤¿¥ÅÄ͵¹Ô¡¤ÈÄÅ침¼ù¡¤Ë̸µ¡¡·ò¡¤ÊÒ¾åůÌ顤ƣ»³ ²íÀ²¡¤Ê¿Àɧ¡¤ÌÚ²¼Íøɧ¡¤ÃæëÔèÃË ; ¡Ú¼«»¦ËÉ»ß:µßÌ¿µßµÞ¤Ë¤ª¤±¤ë¥Á¡¼¥à°åÎÅ¡Û µßÌ¿µßµÞ¥»¥ó¥¿¡¼¤Ë¤ª¤±¤ë¼«»¦Í½ËÉ¡¡ºÆ´ë¿ÞͽËɤ˲̤¿¤¹PSW¤ÎÌò³ä¡¥Áí¹çɱ¡Àº¿À°å³Ø23(3)253-259
  16. Àж¿²¬½ã¡¤´äÅÄÃçÀ¸¡¤²ÃÆ£Àµ¼ù¡¤ÌÚ²¼Íøɧ ; SSRI ¤Ë¤è¤ëÃæ»ß¸å¾É¾õ¤È¤½¤Î¥Þ¥Í¥¸¥á¥ó¥È.
    Î×¾²Àº¿ÀÌôÍý14(5)925-935
  17. ÈøºêµªÉס¤ºäËÜ¡¡·°¡¤ÀîÖ¿¹°¾Û¡¤²ÃÆ£Àµ¼ù ; ÁжËÀ­¾ã³²¤Ë¤ª¤±¤ë¿·¤¿¤Ê¼£ÎÅÁªÂò»è-Lamotrigine ¤ÎŬ±þ³ÈÂç¤òÁ°¤Ë¡¥Î×¾²Àº¿ÀÌôÍý14(9)1567-1575
  18. Áýß·½¡ÍΡ¤Åĸý¿Î»Î¡¤¿ùËÜãºÈ¡¤Ë̱ºÍ´°ì¡¤¹âÀ¥¾¡¶µ¡¤¾®ÅçÇîÇ·¡¤¾¾ËÜÁáÉÄ¡¤¾®Å縦ÂÀϺ¡¤¿·µÜ ¶½ ; ¥ì¥¬¥Ð¥ê¥óÆâÉþ¤Ë¤è¤ê²¼»è¤ÎÉâ¼ð¤òÀ¸¤¸¤¿¾ÉÎã. ¥Ú¥¤¥ó¥¯¥ê¥Ë¥Ã¥¯32(12)1883-1885
  19. Baghai Thomas C¡¤ÌÚ²¼Íøɧ ; Â礦¤ÄÉÂÀ­¾ã³²¤ËÂФ¹¤ëÌôʪÎÅË¡
    Mirtazapine ¤ÎÎ×¾²Åª¤Ê°ÕµÁ. Î×¾²Àº¿ÀÌôÍý14(1)151-169

¥Ú¡¼¥¸TOP¤ØÌá¤ë

Ãø½ñ

  1. ÈÄÅ침¼ù¡¤²ÃÆ£Àµ¼ù¡¤ÌÚ²¼Íøɧ ; ­¸¾Ï ¥×¥é¥¤¥Þ¥ê¥±¥¢°å¤¬ÃΤäƤª¤¯¤Ù¤­¸¸³ÐÌÑÁۤΥݥ¤¥ó¥È ¥×¥é¥¤¥Þ¥ê¥±¥¢°å¤¬ÃΤäƤª¤¯¤Ù¤­¸¸³ÐÌÑÁÛ¤ÎÌôʪÎÅË¡. Ǿ¤È¤³¤³¤í¤Î¥×¥é¥¤¡¥¥Þ¥ê¥±¥¢ 6. ¸¸³Ð¤ÈÌÑÁÛ ; 202-214 ­ê¥·¥Ê¥¸¡¼
  2. ²ÃÆ£Àµ¼ù¡¤ÌÚ²¼Íøɧ ; Âè11 ¾Ï ¤¦¤ÄɤÎÌôʪÎÅË¡. ¤¦¤Äɤλöŵ ¤¦¤ÄɤÈÁжËÀ­¾ã³²¤¬¤ï¤«¤ëËÜ ; 106-114 ÆüËÜɾÏÀ¼Ò
  3. ²ÃÆ£Àµ¼ù ; [­µÅý¹ç¼ºÄ´¾É] 4. Ìôʪ°äÅÁ³Ø¤«¤é¤ß¤¿¹çÍýŪ¤ÊÌôʪÁªÂò¤Ï¡©EBM Àº¿À¼À´µ¤Î¼£ÎÅ 2011-2012 ; 28-33 Ãæ³°°å³Ø¼Ò
  4. ²¬Â¼¹¨Èþ ; ¥³¥é¥à6 ½¡¶µ¤È¼«Á³´Ñ. ½¡¶µ¿´Íý³Ø³µÏÀ ; 83 ¥Ê¥«¥Ë¥·¥ä½ÐÈÇ
  5. ²¬Â¼¹¨Èþ ; Âè4 ¾Ï ÌÌÀÜÁ°¤ËÉÁ¤«¤ì¤ë¥Ð¥¦¥à¥Æ¥¹¥È¤Î°ÕÌ£. Î×¾²¥Ð¥¦¥à:47-61 À¿¿®½ñ˼
  6. ¾åÌîÀéÊ桤ÌÚ²¼Íøɧ ; ¤Æ¤ó¤«¤ó¤È¥Ñ¡¼¥½¥Ê¥ê¥Æ¥£. Àº¿À°å³Ø¥­¡¼¥ï¡¼¥É»öŵ:287-288 Ã滳½ñŹ

¥Ú¡¼¥¸TOP¤ØÌá¤ë

2010ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Kato M, Serretti A ; Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular psychiatry 15(5)473-500
  2. Miyake M, Rock A, Tajika A, Hozu S, Kanda S, Ueda T, Nishiyama T ; Comparative research between Australia and Japan: a comparison of the quality of health care in nursing facilities using actigraphy. Geriatrics & Gerontology International 10(2)167-176
  3. Okugawa G ; Effect of blonanserin on delirium in a patient with Alzheimer disease. Open sychiatry Journal 4:25-26
  4. Roberto D. Pascual-Marqui, Dietrich Lehmann, Martha Koukkou, Kieko Kochi, Peter Anderer, Bernd Saletu, Hideaki Tanaka, Koichi Hirata, E. Roy John, Leslie Prichep, Rolando Biscay-Lirio, Kinoshita T ; Assessing interactions in the brain with exact low resolution electromagnetic tomography)eLORETA). Philosophical Transactions ,SeriesA, Mathematical,physical and engineering 369(1952)3768-84.
  5. Suwa A, Wakeno M, Tajika A, Kato M, Sugimoto T, Nishida K, Sakai S, Fujiyama Y, Takekita Y, Kinoshita T ; Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine: A case report.International journal of geriatric psychiatry 25(4)433-434
  6. Yamamoto K, Kanbara K, Mutsuura H, Ban I, Mizuno Y, Abe T, Yoshino M, Tajika A, Nakai Y, Fukunaga M ; Psychological characteristics of Japanese patients with chronic pain assessed by the Rorschach test.BioPsychoSocial medicine 4:Article No.20
  7. ÈÄÅ침¼ù¡¤Â¼Èø²Â§¡¤ÀÄú˱§°Ê¡¤Ê¿Àɧ¡¤´äÀ¥Àµ¸²¡¤ÃæëÔèÃË ; ¿·¤·¤¤¥°¥ê¥Û¥µ¡¼¥È¥«¥ê¥¦¥à±öÀ½ºÞ¤Ë¤è¤ëÃæÆǤÇÃø¤·¤¤¹â¥«¥ê¥¦¥à·ì¾É¤òÄ褷¤¿1 Îã.ÃæÆǸ¦µæ23(3)246-250
  8. ÈÄÅ침¼ù¡¤Æþß·¡¡Á »³ÅÄÈÞº»»Ò¡¤¿ùËÜãºÈ¡¤¿¥ÅÄ͵¹Ô¡¤Ê¿Àɧ¡¤´äÀ¥Àµ¸²¡¤Â¼Èø²Â§¡¤ÃæëÔèÃË¡¤ÌÚ²¼Íøɧ ; ¼«»¦´ë¿Þ¤Ë¤ÆµßµÞÈÂÁ÷¤µ¤ì¤¿ÁжËÀ­¾ã³²¤Î2¾ÉÎã. Bipolar disorder / Japan8:39-45
  9. ÊÒ¾åůÌ顤¿¥ÅÄ͵¹Ô¡¤ÌÚ²¼Íøɧ ; ÁжËÀ­º®¹ç¾õÂ֤ˤª¤±¤ëÉÔ°ÂŽ¥¾ÇÁç´¶Âкö¤Î½ÅÍ×À­-Lithium¤Ëtandospirone¤òÄɲ乤붯²½ÎÅË¡¤Ë¤è¤ê¸ú²Ì¤¬¤ß¤é¤ì¤¿34¾ÉÎã¤Î¹Í»¡-.Î×¾²Àº¿ÀÌôÍý13(8)1547-1558
  10. ÊÒ¾åůÌ顤¿¥ÅÄ͵¹Ô¡¤ÌÚ²¼Íøɧ ; Qyetiapine¤Ø¤ÎÀÚ¤êÂؤ¨¤Ë¤è¤êÀº¿À¾É¾õ¤Î²þÁ±¤ª¤è¤Ó¼Ò²ñÀ¸³èǽÎϤθþ¾å¤¬¤ß¤é¤ì¤¿Åý¹ç¼ºÄ´¾É¤Î2¾ÉÎã¡¡Rehabilitation Evalution Hall and Baker(REHAB)¤òÍѤ¤¤Æ.
    Î×¾²Àº¿ÀÌôÍý13(4)803-810
  11. µÈ¼¶©»Ë¡¤¿ùËÜãºÈ¡¤ÁýËÜÏÂÈþ¡¤ÅĶᰡÍö¡¤À¾ÅÄ·½°ìϺ¡¤ÖÖË̲µ±¡¤º´Æ£¹¬Â塤ÎëÌÚÈþº´¡¤¿¥ÅÄ͵¹Ô¡¤ÌÚ²¼Íøɧ ; Àº¿À²Ê¤Ë¤ª¤±¤ë´Ç¸îɬÍ×Î̤Îɾ²Á
    Áí¹çɱ¡Àº¿À°å³Ø22(3)245-250

¥Ú¡¼¥¸TOP¤ØÌá¤ë

ÁíÀ⡦²òÀâ

  1. ÊÒ¾åůÌé, ¿¥ÅÄ͵¹Ô, ÌÚ²¼Íøɧ ; ÁжËÀ­º®¹ç¾õÂ֤ˤª¤±¤ëÉ԰¡¦¾ÇÁç´¶Âкö¤Î½ÅÍ×À­. Bipolar disorder / Japan 8:22-30
  2. ²ÃÆ£Àµ¼ù¡¤ÌÚ²¼Íøɧ ; ¹³¤¦¤ÄÌô¤Î¥á¥¿¥¢¥Ê¥ê¥·¥¹¤Î²ò¼á¤È¸Â³¦.Î×¾²Àº¿ÀÌôÍý13(12)2245-2252
  3. ²ÃÆ£Àµ¼ù¡¤ÌÚ²¼Íøɧ ; NaSSA¤Î²Ì¤¿¤¹¤Ù¤­Ìò³ä¤È¤½¤Î²ÄǽÀ­. Î×¾²Àº¿ÀÌôÍý13(10)1891-1900
  4. ²ÃÆ£Àµ¼ù ; ÌôÍý°äÅÁ³Ø¤ÎºÇ¶á¤Î¿ÊÊâ ¤¦¤Äɼ£ÎŤˤª¤±¤ëÌôÍý°äÅÁ¤È¸ÄÊ̲½°åÎŤβÄǽÀ­. ÆüËÜ¿À·ÐÀº¿ÀÌôÍý³Ø»¨»ï30(2)83-92
  5. ÌÚ²¼Íøɧ ; ¹ñÆâ¤Ë¤ª¤±¤ëmirtazapine¤ÎÎ×¾²À®ÀӤȺ£¸å¤Î´üÂÔ. Î×¾²Àº¿ÀÌôÍý13(5)1014-1023
  6. ²¬Â¼¹¨Èþ ; ¥ê¥ó¥·¥ç¥¦¥²¥ó¥Ð(58)CRC(Clinical Research Coordinator). Î×¾²¿´Íý³Ø10(4)618-20
  7. ÎëÌÚÊþ»Ò¡¤µÈÌî¿¿µª¡¤ÆâÅÄÎɰ졤¾åÌîÀéÊ桤ÌÚ²¼Íøɧ ; ¹­ÈÆÀ­È¯Ã£¾ã³²¤Î¥í¡¼¥ë¥·¥ã¥Ã¥Ï¡¦¥Æ¥¹¥È¤Ë¤ª¤±¤ëÆÃħ¡¡¡ÝºÆ¸¡ºº¤òÄ̤·¤Æ¡Ý. ¥í¡¼¥ë¥·¥ã¥Ã¥ÏË¡¸¦µæ14:18-25
  8. Ê¿°ÂÎÉͺ, Í­²ìÅ°, »°Â¼Õò, ²ÏÀ¾À齩, ÅÄÃæ¹îÌÀ, ²ÃÆ£Âç»ü, º´Æ£Îè»Ò, »³ÅÄÊþ¼ù, ¼ò°æÌÀÉ×, ÂçÄ͹ÌÂÀϺ, ÃÒÅÄʸÆÁ, ×¢¾ï½¨¿Í, ¾®ÀîÄ«À¸, µÜ²¬Åù, »³Ëܸ­»Ê, ¾åÛêµÈ¿Í, Ä«ÅÄδ, ÂÀÅáÀî¹°ÏÂ, ´ßËÜǯ»Ë, °æ¾åâÃ, ÃÓ²¼¹î¼Â, Âçµ×ÊÝÁ±Ï¯, ºäËÜÇî»Ò, °ËÆ£·Éͺ, ²£ÅÄ͵¹Ô, °¬µÈÛêÂÀϺ, ¿ùËÜãºÈ, ¿Í¸«²Â»Þ, ¹õÌÚ§¿Ã, ËÙÀîľ»Ë, ´ä·§¾¼ÍÎ, êÌƣĪÌÀ, ´äÅÄÃçÀ¸, ²ÏÌ»Ì, ÀîÌî·ò¼£, ¾¾²¬Ë­, ÀÐÄÍľ¼ù, ¼ò°æ¹°·û, ÊÆËÜľ͵ ; ¼«»¦´ë¿Þ¤ÎºÆȯËɻߤËÂФ¹¤ëÊ£¹çŪ¥±¡¼¥¹Ž¥¥Þ¥Í¥¸¥á¥ó¥È¤Î¸ú²Ì:¿»ÜÀ߶¦Æ±¤Ë¤è¤ë̵ºî°Ù²½Èæ³Ó»î¸³. ¼«»¦Âкö¤Î¤¿¤á¤ÎÀïά¸¦µæ Ê¿À®21ǯÅÙ Áí³çŽ¥Ê¬Ã´¸¦µæÊó¹ð½ñ(¸üÀ¸Ï«Æ¯¾Ê) ; 28-40
  9. »°ÂðâÃÍý¡¤ÅĶᰡÍö¡¤»°Åç¿­²ð¡¤ÊÝÄÅ¿¿°ìϺ¡¤À¾»³ÍøÀµ¡¤¾åÅÄ¾È»Ò ; ͹Êؤò³èÍѤ·¤¿¹âÎð¼Ô¤Î¥á¥ó¥¿¥ë¥±¥¢¤Î¸ú²Ì¤Ë¤Ä¤¤¤Æ¤Î¸¦µæ¡¡²ð¸îÍ×˾¾ðÊó»æ¡Ö¤ªÃ£¼ÔÄÌ¿®¡×¤Î³èÍÑ. Âçºå¥¬¥¹¥°¥ë¡¼¥×Ê¡»ãºâÃÄ¡¡¸¦µæ¡¦Ä´ººÊó¹ð½ñ Âè23ÈÇ(Âçºå¥¬¥¹¥°¥ë¡¼¥×Ê¡»ãºâÃÄ)59-71
  10. ÂçÄ͹ÌÂÀϺ, Àî¼¾ÍÂå, Ã漸÷, ÂÀÅáÀî¹°ÏÂ, º¬ËÜÀ¶µ®, »³Ëܸ­»Ê, ÀîÌî·ò¼£, ÀîÌî·ò¼£, ºäËÜÇî»Ò, §ËÜÏ¿­, ²ÃÆ£Âç»ü, Ê¿Ìî¤ß¤®¤ï, »³ÅÄÁÇÊþ»Ò, ¿ùËÜãºÈ, »³ÅÄÈÞº»»Ò, µÈÅÄÃÒÇ·, º´Æ£Îè»Ò, ¿Í¸«²Â»Þ, Ê¿ÎÓ·Ä»Ë, ¿ÀëÈþÃÒ»Ò, ²¼ÅĽÅϯ, Åڰ渶ÀéÊæ, ²ÏÀ¾À齩 ; ¼«»¦Âкö¤Î¤¿¤á¤ÎÀïά¸¦µæ ¼«»¦´ë¿Þ¤ÎºÆȯËɻߤËÂФ¹¤ëÊ£¹çŪ¥±¡¼¥¹Ž¥¥Þ¥Í¡¼¥¸¥á¥ó¥È¤Î¸ú²Ì:¿»ÜÀ߶¦Æ±¤Ë¤è¤ë̵ºî°Ù²½Èæ³Ó¸¦µæ ²ðÆþ¥×¥í¥°¥é¥à°Ñ°÷²ñ¿´Íý¶µ°é¥×¥í¥°¥é¥àºîÀ®¤Èɸ½à²½¤Ë´Ø¤¹¤ëÊó¹ð. ¼«»¦Âкö¤Î¤¿¤á¤ÎÀïά¸¦µæ Ê¿À®17-21ǯÅÙ Áí¹ç¸¦µæÊó¹ð½ñ(¸üÀ¸Ï«Æ¯¾Ê)293-302
  11. ¿ùËÜãºÈ, »³ÅÄÈÞº»»Ò, ¿¥ÅÄ͵¹Ô, ÈÄÅ침¼ù, Æ£»³²íÀ², ²ÃÆ£Àµ¼ù, ÃæëÔèÃË, ÌÚ²¼Íøɧ, µÈÅľ﹧,
    ÆîÃÒµ× ; ¼«»¦Âкö¤Î¤¿¤á¤ÎÀïά¸¦µæ ¼«»¦´ë¿Þ¤ÎºÆȯËɻߤËÂФ¹¤ëÊ£¹çŪ¥±¡¼¥¹Ž¥¥Þ¥Í¡¼¥¸¥á¥ó¥È¤Î¸ú²Ì:¿»ÜÀ߶¦Æ±¤Ë¤è¤ë̵ºî°Ù²½Èæ³Ó¸¦µæ ´ØÀ¾°å²ÊÂç³ØÁí¹ç°åÎÅ¥»¥ó¥¿¡¼. ¼«»¦Âкö¤Î¤¿¤á¤ÎÀïά¸¦µæ Ê¿À®17-21ǯÅÙ Áí¹ç¸¦µæÊó¹ð½ñ(¸üÀ¸Ï«Æ¯¾Ê)357-366
  12. ÆñÇȽӻʡ¤ÌÚ²¼Íøɧ¡¤Ê¡ÅÄÀµÇÅÏÊÕÍΰìϺ ; ¹³¤¦¤ÄÌô¤ÎºÇ¿·¤ÎÃ諤òƧ¤Þ¤¨¤¿¡¢¼«»¦Í½ËɤΤ¿¤á¤Î¤¦¤ÄɤÎÁá´üȯ¸«¤È¼£ÎÅ¡¥Î×¾²Àº¿ÀÌôÍý13(4)841-852
  13. ¼ºê¸÷Ë®¡¤Ã滳ÏÂɧ¡¤ÌÚ²¼Íøɧ, NELSON J. Craig ; Mirtazapine¤Î´ðÁÃŽ¥Î×¾²ÅªÆÃħ¤«¤é¸«¤¿¼ÂÎ×¾²¤Ç¤Î»È¤¤Êý¤Ë¤Ä¤¤¤Æ. Î×¾²Àº¿ÀÌôÍý13(5)1082-1088
  14. ¼ºê¸÷Ë®¡¤ÌÚ²¼Íøɧ¡¤°æ¾å¡¡ÌÔ¡¤BLIER Pierre ; Mirtazapine¤Î´ðÁÃŽ¥Î×¾²ÅªÆÃħ¤«¤é¸«¤¿¼ÂÎ×¾²¤Ç¤Î»È¤¤Êý¤Ë¤Ä¤¤¤Æ. Î×¾²Àº¿ÀÌôÍý 13(5)1043-1052
  15. ÆñÇȽӻʡ¤ÌÚ²¼Íøɧ¡¤Ê¡ÅÄÀµÇÅÏÊÕÍΰìϺ ; ¹³¤¦¤ÄÌô¤ÎºÇ¿·¤ÎÃ諤òƧ¤Þ¤¨¤¿¡¢¼«»¦Í½ËɤΤ¿¤á¤Î¤¦¤ÄɤÎÁá´üȯ¸«¤È¼£ÎÅ. Î×¾²Àº¿ÀÌôÍý13(4)841-852

¥Ú¡¼¥¸TOP¤ØÌá¤ë